-
FTC reverses its decadelong support for PBMs
The Federal Trade Commission is backing away from its past advocacy statements for pharmacy benefit managers after a change in "current market realities." -
Massachusetts Medical Society supports over-the-counter birth control
The Massachusetts Medical Society and its Committee on Maternal and Perinatal Welfare voiced their support of the FDA's decision to permit sales of over-the-counter progestin-only birth control, according to a July 18 news release. -
Another weight loss drug goes into shortage
High demand has pushed another Novo Nordisk weight loss drug into shortage. -
Plant making 25% of Pfizer's injectables used by hospitals destroyed by tornado
Severe winds from an EF-3 tornado on July 19 crushed a North Carolina Pfizer manufacturing plant that made nearly 25 percent of the drugmaker's sterile injectables used by U.S. hospitals. -
'Gray market' grows for cancer drugs
Without a clear resolution to the monthslong shortage of life-saving cancer drugs, hospital pharmacy leaders told Becker's the "gray market" is barging into their emails and phone logs. -
Cost Plus Drugs' pharmacy network swells to more than 2K locations
Mark Cuban Cost Plus Drug Co.'s pharmacy network now includes hundreds of independent and grocery chain pharmacy locations. -
Cost Plus Drugs could be selling drugs to hospitals by this fall
Mark Cuban Cost Plus Drug Co. plans to be selling drugs to hospitals and clinics by September or October, the company's CEO and co-founder Alex Oshmyansky, MD, PhD, told Dallas-based D Magazine. -
9 new drug shortages
Nine drugs were recently added to the hundreds-long, growing list of medications in short supply, according to the FDA and the American Society of Health-System Pharmacists. -
Baptist 1st system to use blockchain for drug pricing
Baptist Health, a nine-hospital system in Louisville, Ky., is the first health system in the U.S. to use MediLedger's blockchain technology to review prices for procured drugs. -
Eli Lilly reports Alzheimer's drug candidate slows decline by 60%
A phase 3 trial for donanemab, Eli Lilly's Alzheimer's drug candidate, showed significant progress in slowing down cognitive and functional decline in people who are in early stages of the disease's progression, according to a July 17 news release. -
Keck Medicine's pharmacy chief begins climbing learning curve
Krist Azizian, PharmD, wants to standardize 80 percent of pharmacy procedures across multiple ambulatory clinics and a cancer hospital, a 158-bed community hospital, a cancer center, a specialty surgery hospital and a 348-bed community hospital. -
FDA approves 1st RSV drug for babies, toddlers
The U.S. now has an approved pediatric drug to prevent respiratory syncytial virus lower respiratory tract disease, which infects nearly every child before they turn 2 years old. -
Eli Lilly to buy weight loss drugmaker for $1.93B
Eli Lilly has entered a definitive agreement to acquire obesity drugmaker Versanis for $1.93 billion — a move that will boost Eli Lilly's weight loss drug treatment portfolio. -
What raises the bar for 6 hospital pharmacies
The American Society of Health-System Pharmacists recently named six hospitals as centers of excellence for their medication use safety and pharmacy practice. The pharmacy leaders at these facilities shared with Becker's their keys to earning the three-year accreditation: -
West Virginia hospital CEO becomes chair of 340B Health
Nonprofit organization 340B Health selected Karen Bowling, president and CEO of a West Virginia University Health System hospital, as the new chair of its board of directors. -
MS drug infusion can shorten from hours to 10 minutes: Phase 3 study
An FDA-approved multiple sclerosis drug that requires 2.5 hours for the first infusion and 3.5 hours for subsequent doses might be able to shorten its duration to 10 minutes, its maker said July 14. -
Compounded cardioplegia shortage could create hurdles for hospitals
There are no commercially available solutions of compounded cardioplegia, a drug used to temporarily stop the heart during surgery, after the FDA cited the nation's only pharmacy that compounded the medication. -
Patients struggle to find affordable insulin despite Eli Lilly price cap: Report
Uninsured Americans are still having challenges accessing affordable insulin, despite Eli Lilly's decision to cap its generic version, Lispro, at $25 per vial, according to a report Sen. Elizabeth Warren's office released July 13. -
Mark Cuban Cost Plus Drugs adds 10th brand-name drug
Mark Cuban Cost Plus Drug Co. added its 10th brand-name drug to its portfolio that includes about 1,000 generics. -
FDA clears first OTC birth control pill
On July 13, the FDA approved an oral contraceptive pill called Opill to be sold over the counter, making it a first in the U.S.
Page 39 of 50